Immuron Files F-1 with the SEC

MELBOURNE, Australia, Dec. 21, 2016 -- Australian biopharmaceutical Company, Immuron Limited (ASX:IMC), is pleased to announce today that it filed its Registration Statement on Form F-1 with the United States Securities and Exchange Commission (SEC) relating to the initial public offering of its American Depository Shares (ADS).  The Registration Statement is preliminary and has not yet become effective. The Company also intends to seek the listing of its ADS on a US national stock exchange.

The number of shares proposed to be offered and sold, and the dollar amount proposed to be raised under this US Public Offering have not yet been determined and there cannot be any assurance that the Company’s IPO will be completed.
  
Joseph Gunnar & Co., LLC is acting as book-running manager for the offering.

The Immuron filing can be found under the Edgar database housed in the SEC website.  The registration statement, including a prospectus, which is preliminary and subject to completion, relating to these securities has been filed with the U.S. Securities and Exchange Commission, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time that the registration statement becomes effective, and, even then, the securities may only be sold pursuant to the registration statement and final prospectus. This announcement shall not constitute an offer to sell or a solicitation of an offer to buy these securities in the United States or in any other jurisdiction, including without limitation Australia, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. A copy of the prospectus relating to this offering, when available, will be filed with the SEC and may also be obtained from Joseph Gunnar & Co., LLC, Prospectus Department, 30 Broad Street, 11th Floor, New York, NY 10004, telephone 212-440-9600, email: [email protected].

About Immuron:

Immuron Ltd (ASX:IMC) is a biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the treatment of immune mediated diseases.  Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of travellers’ diarrhoea, whilst its lead product candidate IMM-124E is in Phase II clinical trials for NASH, ASH and Pediatric NASH. These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market.

For more information, visit: http://www.immuron.com/

Forward-Looking Statements:

Certain statements made in this release are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control, including those risks or uncertainties inherent in the process of both developing and commercialising technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.

Company Contact:
Thomas Liquard
Chief Executive Officer
Ph: +61 (0)3 9824 5254
[email protected]

Immuron Media Relations:
John Beveridge
Monsoon Communications
Ph: +61 (0)3 9620 3333
[email protected]